Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from nucleos(t)ide analogues to pegylated interferon alfa in chronic hepatitis B with low HBsAg and low HBeAg
ChiCTR1800015071Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pegylated interferon alpha in Chronic Hepatitis B (CHB) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: hepatitis B surface antigen, hepatitis B surface antibody and 2 more. Planned start Mar 2018; status: not yet recruiting.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR1800015071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800015071.